Cidara Therapeutics, Inc. (CDTX)
Jan 7, 2026 - CDTX was delisted (reason: acquired by MRK)
221.38
+0.06 (0.03%)
Inactive · Last trade price
on Jan 6, 2026
Cidara Therapeutics Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Cidara Therapeutics stock had an average target of 128.75, with a low estimate of 35 and a high estimate of 200.
Analyst Consensus: Buy
* Price targets were last updated on Nov 7, 2025.
Analyst Ratings
The average analyst rating for Cidara Therapeutics stock from 12 stock analysts was "Buy". This means that analysts believed this stock was likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 4 | 4 | 3 |
| Buy | 5 | 4 | 6 | 6 | 6 | 6 |
| Hold | 0 | 0 | 0 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 11 | 13 | 13 | 13 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Guggenheim | Guggenheim | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Nov 18, 2025 |
| Needham | Needham | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Nov 14, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Nov 14, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $137 → $145 | Buy | Maintains | $137 → $145 | -34.50% | Nov 7, 2025 |
| Needham | Needham | Strong Buy Maintains $100 → $135 | Strong Buy | Maintains | $100 → $135 | -39.02% | Nov 7, 2025 |
Financial Forecast
Revenue This Year
n/a
from 1.28M
Revenue Next Year
8.60M
EPS This Year
-8.30
from -26.75
EPS Next Year
-6.40
from -8.30
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | 31.5M | ||||
| Avg | n/a | 8.6M | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -6.26 | -4.25 | ||||
| Avg | -8.30 | -6.40 | ||||
| Low | -8.98 | -9.86 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.